

Detail Results: Patient Info				Results Info	
Patient Name:	Poulomi Ghosh	Home Phone:	6477077169	Date of Service:	2024-06-13 16:29:00
Date of Birth:	1987-01-07	Work Phone:		Date Received:	2024-06-17 11:44
Age:	37 years	Sex:	F	Report Status:	Final
Health #:	7984798442	Patient Location:	MedHealth Laboratories	Client Ref. #:	043555
				Accession #:	
Requesting Client: Sabiha Rehan				cc: Client:	

HEMATOLOGY						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
WBC	7.2	N	4.0-11.0	10**9/L		Final
RBC	5.47	H	4.0-5.1	10**12/L		Final
Hemoglobin	115	L	120-160	g/L		Final
Hematocrit	0.379	N	0.36-0.48	L/L		Final
Platelet Count	129	L	150-400	10**9/L		Final
MCV	69.2	L	80-98	fL		Final
MCH	21.0	L	27.5-32.5	pg		Final
MCHC	303	L	320-360	g/L		Final
RDW	15.3	H	11.5-14.5	%		Final

DIFFERENTIAL COUNT						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
Neutrophil	4.5	N	2.0-7.5	10**9/L		Final
Lymphocyte	2.0	N	1.0-3.5	10**9/L		Final
Monocyte	0.6	N	0.0-0.8	10**9/L		Final
Eosinophil	0.1	N	0.0-0.5	10**9/L		Final
Basophil	0.0	N	0.0-0.2	10**9/L		Final

Morphology						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
Morphology	RBC: Moderate microcytosis, mild hypochromia. WBC: Normal Platelets: Slightly decreased with megathrombocytes/giant forms	N				Final

URINALYSIS						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
SpecificGravity	1.010	N	1.010-1.030			Final
pH	6.0	N	5.5-8.0	pH		Final
Sugar (Urine)	Negative	N				Final
Protein (Urine)	Negative	N				Final
Ketone	Negative	N				Final
Blood	Negative	N				Final
Leukocytes	Negative	N				Final
Nitrite	Negative	N				Final

GENERAL CHEMISTRY						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
Glucose Fasting	4.7	N	3.6-6.0	mmol/L		Final
HbA1C	5.2	N	<6.0	%		Final
Screening: Normal glycemic control						
Goal for monitoring Non-Diabetics refer to OAML communique dated May 2015, Available on request						
Creatinine	47	N	39-87	umol/L		Final
eGFR	122	N	>=90			Final
Normal eGFR is described as greater than or equal to 90 ml/min/1.73m ²						
*****Effective April 08, 2024, eGFR is calculated using the New 2021 CKD-EPI equation						
KDIGO 2012 guidelines highlighted the importance of eGFR and urine albumin creatinine ratio(ACR)in screening, diagnosis and management of CKD. Result for eGFR should be interpreted in concert with ACR						
Sodium	138	N	136-144	mmol/L		Final
Potassium	3.9	N	3.5-5.1	mmol/L		Final
ALT (SGPT)	24	N	7-52	U/L		Final
Uric Acid	248	N	137-393	umol/L		Final
Cholesterol	4.60	N	<5.20	mmol/L		Final
Triglycerides	1.00	N	<1.50	mmol/L		Final
HDL Cholesterol	1.93	N	0.59-2.38	mmol/L		Final
LDL Cholesterol	2.21	N	<3.36	mmol/L		Final
Chol:HDL Ratio	2.4	N				Final
NON-HDL Choleste	2.66	N		mmol/L		Final
Non-HDL cholesterol is calculated from total cholesterol and HDL-C and is not significantly affected by the fasting status of the patient						
overnight fasting and early morning testing no longer needed for many lipid screening tests						
LIPID TARGET VALUES						
10 years CVD risk	Primary Tx Target	Alrenate Tx Target				
High or intermediate (FRS>=10%) LDL <= 2.0 mmol/L or Non-HDL-C <= 2.6 mmol/L						
>=50% decrease in LDL-C						
Low(FRS<10%) >=50% decrease in LDL-C						
Chol/HDL-C is not included in the 2012 CCS guidelines as a lipid initiation or treatment target but is recognized as an indicator of high CVD risk at Chol/HDL-C ratio>6.0						
Fasting	>10	N		Hours		Final
Consider the non-HDL-C value as an alternate lipid target if monitoring treatment is intermediate or high risk patients						
TSH Ultra-sens	1.69	N	0.35-4.94	mIU/L		Final
Asymptomatic patients should generally not be screened for thyroid disease (exceptions include pregnant, post-partum, or post-menopausal women). Thyroid function in patients with suspected thyroid disease is best assessed with TSH as the sole screening test. It is not						

GENERAL CHEMISTRY						
Test Name(s)	Result	Abn	Reference Range	Units	Date/Time Completed	Status
appropriate to order free-T4 and/or free-T3 in addition to TSH in the initial screen						
Free T3	5.6	N	3.4-6.0	pmol/L		Final
Free T4	12	N	8-15	pmol/L		Final
Vitamin B12	179	N	133-675	pmol/L		Final
Vitamin B12 assays should be considered for assessment of peripheral neuropathy, megaloblastic anemia, or malabsorptive conditions. Routine screening should only be ordered on seniors and then only once every few years. In lieu of testing, oral supplementation should be considered for individuals suspected of vitamin B12 deficiency						
Ferritin	31	N	11-307	ug/L		Final
VitD 25Hydroxy	54	L	76-175	nmol/L		Final
Deficient: < 50 nmol/L Insufficient: 50-75 nmol/L Optimal: 76-175 nmol/L Toxic Levels: >375 nmol/L Note: Starting on October 1, 2023 routine chemistry testing will be performed on a new updated analyzer. The analyzer has been thoroughly validated and clients should note that there are some modifications to the reference ranges with the new methodologies. All reference ranges are shown on the patient reports. Any questions should be directed to the labs chemistry department						
END OF REPORT						